PMC6304185_01
Height growth chart of patient. Recombinant human growth hormone (rhGH) therapy start indicated.
CRIE2018-7658496.001.jpg
PMC6304185_03_CRIE2018-7658496.001.jpg
fig1
The patient was started on recombinant human growth hormone (rhGH) therapy at age 7.75 years with an increase in her annualized growth velocity from 4.4 cm/yr pre-rhGH to 9.3 cm/yr after year 1 (increase in height SDS from -2.5 to -1.1) and then to 10.5 cm/yr at the end of year 2 (height SDS of 0) (Figure 1).
Shortened metacarpals (except the 2nd) of the left hand.
CRIE2018-7658496.002.jpg
PMC6304185_01_CRIE2018-7658496.002.jpg
fig2
Radiological imaging revealed shortened metacarpals of her left hand on a bone age X-ray (Figure 2).
Short and broad thumb of the mother.
CRIE2018-7658496.003.jpg
PMC6304185_01_CRIE2018-7658496.003.jpg
fig3
Her examination also demonstrated short, broad thumbs (Figure 3) and first toes bilaterally, and mild mesomelia of the upper limbs.
PMC6304185_02
PMC6304185_03
Height growth chart of patient. Recombinant human growth hormone (rhGH) therapy start indicated.
CRIE2018-7658496.001.jpg
PMC6304185_03_CRIE2018-7658496.001.jpg
fig1
The patient was started on recombinant human growth hormone (rhGH) therapy at age 7.75 years with an increase in her annualized growth velocity from 4.4 cm/yr pre-rhGH to 9.3 cm/yr after year 1 (increase in height SDS from -2.5 to -1.1) and then to 10.5 cm/yr at the end of year 2 (height SDS of 0) (Figure 1).